US · MLEC
Moolec Science S.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Luxembourg 2411
- Website
- moolecscience.com
Price · as of 2025-06-30
$10.37
Market cap 9.66M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,012.81 | +9,666.73% |
| Intrinsic Value(DCF) | $3,217,212.38 | +31,024,127.39% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $1,474.50 | ||||
| 2022 | $1,504.50 | ||||
| 2023 | $460.50 | ||||
| 2024 | $138.00 | $147.58 | $0.00 | $0.00 | $0.00 |
| 2025 | $17.77 | $1,012.81 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Moolec Science S.A.'s (MLEC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,012.81
- Current price
- $10.37
- AI upside
- +9,666.73%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3,217,212.38
+31,024,127.39% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MLEC | Moolec Science S.A. | $10.37 | 9.66M | +9,667% | +31,024,127% | — | — | -0.07 | -0.12 | 0.02 | -3.56 | 0.00 | -0.05 | 34.17% | -3.14% | -33.41% | 376.84% | -11.15% | -93.08% | -3.74 | -0.25 | 0.13 | 0.12 | -3.57 | 897895.00% | 583074.00% | 21733.00% | -393.07% | -0.10 | -32.03% | 0.00% | 0.00% | 12.10% | -23.43 | -8.16 | 0.74 | -0.48 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| ELAB | PMGC Holdings Inc. | $1.19 | 126.21K | +401,467% | +24,631% | — | — | -0.06 | 0.06 | 0.16 | 1.12 | — | 0.10 | 72.84% | -75.65% | -253.14% | -119.12% | -110.26% | -88.07% | 0.00 | -2.54 | 3.36 | 2.22 | 1.25 | -8600.00% | 4407.00% | 2032.00% | -1366.73% | -3.05 | -324.66% | 0.00% | 0.00% | 215.87% | 1.92 | 0.65 | -1.45 | -1.81 |
| GLMD | Galmed Pharmaceuticals Lt… | $0.61 | 3.35M | — | — | — | — | -0.23 | 0.11 | — | 1.83 | — | 0.11 | 0.00% | — | — | -49.77% | -552.15% | -42.80% | 0.00 | -418.53 | 7.42 | 7.15 | 0.63 | -7302.00% | — | -419.00% | -334.59% | -2.71 | -517.15% | 0.00% | 0.00% | 104.25% | 2.16 | 2.31 | — | -14.90 |
| GTBP | GT Biopharma, Inc. | $0.48 | 5.08M | — | — | — | — | -0.35 | -2.77 | — | -0.05 | -1.53 | -2.77 | 0.00% | — | — | -453.39% | 238.23% | -143.53% | 0.00 | — | 0.72 | 0.67 | 0.30 | 2305.00% | — | 4577.00% | -278.78% | -2.19 | 214.01% | 0.00% | 0.00% | 63.30% | -0.05 | -0.05 | — | -241.19 |
| NCEL | NewcelX Ltd. | $2.90 | 1.31M | — | — | — | — | -0.65 | 0.91 | — | 0.11 | -0.09 | 0.91 | 0.00% | — | — | 53.34% | 104.83% | -97.10% | 0.00 | -29.20 | 2.69 | 2.50 | 0.46 | 72188.00% | — | -5589.00% | -333.71% | -5.16 | 102.24% | 0.00% | 0.00% | 187.60% | 0.09 | 0.09 | — | -51.45 |
| TIVC | Tivic Health Systems, Inc… | $0.82 | 889.68K | +3,622% | +81% | — | -43% | -189.04 | 421.70 | 1370.53 | -200.98 | — | 421.70 | 0.26% | -725.77% | -725.00% | -184.96% | -1041.58% | -142.01% | 0.00 | — | 9.70 | 7.61 | 0.38 | -8887.00% | -3367.00% | -3365.00% | -0.54% | -21.05 | -1053.36% | 0.00% | 0.00% | 0.00% | -188.49 | -186.38 | 1367.97 | 2331.04 |
| VRAX | Virax Biolabs Group Limit… | $0.23 | 988.66K | +58,899% | +71% | — | +71,836% | -0.50 | 0.53 | 478.92 | 0.14 | — | 0.54 | -838.21% | -97344.76% | -95739.17% | -109.69% | -313.42% | -101.88% | 0.07 | -105.93 | 7.27 | 6.33 | 0.66 | -4196.00% | -9595.00% | -3028.00% | -170.43% | -6.78 | -268.72% | 0.00% | 0.00% | 16.06% | 0.13 | 0.16 | -129.50 | -5.85 |
| XRTX | XORTX Therapeutics Inc. | $0.41 | 1.55M | — | — | — | — | -0.75 | 0.97 | — | -0.37 | — | 1.07 | 0.00% | — | — | -119.80% | -346.54% | -95.46% | 0.02 | — | 1.61 | 1.58 | 0.26 | -5273.00% | — | 398.00% | -139.13% | -4.71 | -294.67% | 0.00% | 0.00% | 0.00% | -0.36 | -0.43 | — | -14.31 |
About Moolec Science S.A.
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
- CEO
- Alejandro Antalich
- Employees
- 52
- Beta
- 0.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3,217,212.38 ÷ $10.37) − 1 = +31,024,127.39% (DCF, example).